{
    "thread": {
        "uuid": "2e9836818ca5e6b02e00a72431cab7ea62347a52",
        "url": "https://hk.stockstar.com/RB2025042400006437.shtml",
        "site_full": "hk.stockstar.com",
        "site": "stockstar.com",
        "site_section": "http://hk.stockstar.com/",
        "site_categories": [],
        "section_title": "港股_证券之星",
        "site_title": null,
        "title": "亚盛医药-B(06855.HK)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告_港股频道_证券之星",
        "title_full": "亚盛医药-B(06855.HK)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告_港股频道_证券之星",
        "published": "2025-04-24T02:20:00.000+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "CN",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 13920,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "2e9836818ca5e6b02e00a72431cab7ea62347a52",
    "url": "https://hk.stockstar.com/RB2025042400006437.shtml",
    "ord_in_thread": 0,
    "author": "证券之星港美股",
    "published": "2025-04-24T02:20:00.000+03:00",
    "title": "亚盛医药-B(06855.HK)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告_港股频道_证券之星",
    "text": "亚盛医药-B(06855.HK)发布公告，公司细胞凋亡管线重点品种Bcl-2选择性抑制剂Lisaftoclax(APG-2575)和MDM2-p53抑制剂Alrizomadlin (APG-115)的两项临床研究成果入选2025年美国临床肿瘤学会(ASCO)年会，其中，APG-2575联合治疗髓系恶性肿瘤患者的Ib/II期研究最新进展获口头报告。\n投行对该股的评级以买入为主，近90天内共有6家投行给出买入评级，近90天的目标均价为57.02港元。中泰证券最新一份研报给予亚盛医药-B买入评级。\n机构评级详情见下表：\n亚盛医药-B港股市值149.41亿港元，在化学制药行业中排名第9。主要指标见下表：\n以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Science and Technology"
    ],
    "topics": [
        "Health->cancer",
        "Health->medical specialisation",
        "Health->health treatment and procedure",
        "Science and Technology->scientific publication",
        "Science and Technology->medical research",
        "Science and Technology->biotechnology"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": []
    },
    "syndication": {
        "syndicated": null,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T02:32:33.976+03:00",
    "updated": "2025-04-24T02:32:33.976+03:00"
}